Background/aim: This study aims to investigate whether the combination of oncolytic viruses with chemoradiotherapy or other therapies is a promising strategy for cancer treatment.
Materials and methods: The anticancer effects of measles virus (MeV) in combination with nimotuzumab in the treatment of laryngeal cancer were evaluated in vitro and in nude mice inoculated with Hep2 tumors. MTT assay and flow cytometry were used to examine cell death.
Results: Laryngeal cancer cells treated with MeV+nimotuzumab combination had a significantly lower survival rate compared to those treated with MeV or nimotuzumab alone (p<0.0001). In an animal model bearing human laryngeal tumor, the treated group had a higher survival rate (60%) compared to a untreated group (20%) (p<0.05), and the survival rate of the group treated with MeV+nimotuzumab combination was higher compared to the groups received single treatment.
Conclusion: The MeV+nimotuzumab combination has greater anticancer activities in both laryngeal cancer cells and an animal model.
Keywords: Measles virus; Oncolytic virus; cancer target; laryngeal cancer; monoclonal antibody; nimotuzumab.
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.